Strategies, regulatory intel, and expert guidance across the full lifecycle of MedTech innovation: concept to commercialization. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­    ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  
View in browser
Logo-White
December 25 Insights from the Cutting Edge of Medtech

Preparing human factors questions for your FDA pre-sub? Evaluating eQMS options? Racing to complete IVDR clinical evidence before the deadline? Wondering how CMS' WISeR model changes your market access strategy, or how to turn ISO 10993-1:2025 requirements into competitive advantage?

Let us help bring Velocity to your Vision. This month we share expertise across the innovation pathway and feature conferences where you can meet our experts in person. We've also launched Veranex Biopharma, extending our integrated capabilities.

ANNOUNCING VERANEX BIOPHARMA

A resource for biotech and pharma teams that need trusted expertise.

 

• Biostatistics, biometrics, safety, clinical data management and documentation
• Delivery Device Design
• Commercial Strategy & Reimbursement Readiness
Explore Veranex Biopharma
Headshots for Emails (1)

LEARNING OPPORTUNITY

Clinical Investigation of Medical Devices Requirements of ISO 141552020 Good Clinical Practice (1)

Date/Time: February 17th, 2026 | 11:00am Central European Time

Walk away with a practical approach to planning clinical evaluation to support MDR expectations for sufficient clinical evidence.

Register Here
QMSR compliance deadline

What to Ask FDA About Human Factors in a Pre-Sub

 

Make every minute count with regulators: craft sharper Pre-Sub questions and surface key human factors risks. Our HF and regulatory teams help you surface pitfalls early and enter pre-submissions with sharper questions that make your business go faster.

 

Learn More

EVENTS: MEET OUR EXPERTS IN PERSON 

6

MDMA FDA Forum

Presenting Sponsor

Washington, DC, USA

12-13, March 2026

Event Details
SCDMRSNA

Nelson Labs Summit

Validation of Sterile Medical Devices

Frankfurt, Germany

24-26 February, 2026

Event Details
Screenshot 2026-02-04 at 12.07.29 PM

Dana Point, CA, USA  |  16-20, March 2026

Event Details
Screenshot 2026-02-04 at 12.07.40 PM

International Symposium on Human Factors & Ergonomics in Health Care

New York, NY, USA  |  22-25, March 2026

Event Details

INDUSTRY INSIGHTS FROM THE VERANEX BLOG

1-1

IVDR Transition Deadline: If You’re Behind, Catch Up Now!


Missed timelines don’t have to mean lost revenue. See practical paths to compliance and how to recover without starting over.

2-1

Don't Confuse Software with a System: The eQMS Trap


Buying eQMS software doesn't make a compliant Quality Management System. Don't let it put your regulatory approval and market success at risk.

3-2

Expansion Into Market Adjacencies: Unlocking Growth for the "Big Strategics"

 

Identify and pursue compelling adjacencies that balance strategic fit and acceptable risk, while creating long-term value.

4-2

High Reimbursement Implications: The CMS WISeR Model

 

CMS's Prior Authorization Demonstration could dramatically reshape Medicare reimbursement strategies for the medical device industry.

5-2

ISO 10993-1:2025 - Turn MDR Irritation Into Your Advantage

 

New biocomp standards might feel like regulatory overhead. Smart teams can use them to reduce testing costs and timelines.

6-1

Using Human Factors to Unlock Funding

 

High value, phased human factors testing unlocks funding while building regulatory compliance, solving the startup funding-validation paradox.

Product Design & Engineering
Preclinical & Pathology | Clinical Research (CRO)

 Regulatory Quality | Commercialization

LinkedIn

Veranex Solutions, 5420 Wade Park Blvd., Suite 204, Raleigh, NC 27607, USA

Unsubscribe Manage preferences